Testing asciminib dosing and safety for teen CML patients
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests the right dose and safety of asciminib in children and teens with chronic myeloid leukemia (CML). It may help if your current or last CML medicine (a TKI) did not work well or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and under 18 years old, or 14 to under 18 with at least 40 kg body weight
- Have chronic phase, Philadelphia chromosome positive CML (Ph+ CML-CP)
- Recent blood and bone marrow results must show low blasts and promyelocytes, low basophils, and safe blood counts
- Your prior CML treatment (a TKI) must have failed or you could not tolerate the most recent one
- Have no known resistance mutations like T315I, and your leukemia gene type must match what the test can measure
- No major heart rhythm or organ problems, and no pancreas/liver/GI conditions that affect safety or absorption
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This study looks at the safety and effects of the drug asciminib in young adults (18 and older) with a type of leukemia called chronic myeloid leukemia (CML). It uses information already collected from patients' medical records to see how well the drug works and how safe it is.
Hear when a new Myeloid Leukemia, Philadelphia Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.